Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 10, 2020

SELL
$13.97 - $36.56 $4.66 Million - $12.2 Million
-333,333 Closed
0 $0
Q1 2019

May 20, 2019

SELL
$8.95 - $12.49 $1.82 Million - $2.54 Million
-203,180 Reduced 37.87%
333,333 $4.16 Million
Q4 2018

Feb 08, 2019

BUY
$9.74 - $14.5 $5.23 Million - $7.78 Million
536,513 New
536,513 $5.78 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Aisling Capital Management LP Portfolio

Follow Aisling Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aisling Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Aisling Capital Management LP with notifications on news.